SK-OV-3(luc)人卵巢癌细胞系

"SK-OV-3(luc)人卵巢癌细胞系
传代比例：1:2-1:4(首次传代建议1:2)
生长特性：贴壁生长
换液周期：每周2-3次
冻存和复苏的原则：慢冻快融》当细胞冷到零度以下，可以产生以下变化：细胞器脱水，细胞中可溶性物质浓度升GAO，并在细胞内形成冰晶。如果缓慢冷冻，可使细胞逐步脱水，细胞内不致产生大的冰晶；相反，结晶就大，大结晶会造成细胞膜、纲胞器的损伤和破裂。复苏过程应快融，目的是防止小冰晶形成大冰晶，即冰晶的重结晶。慢冻程序》1.标准程序：采用细胞冻存器》当温度在-25℃以上时，1~2℃/min；当温度达-25℃以下时，5~10℃/min；当温度达-100℃时，可迅速放入中。2.简易程序：将冷冻管（管口要朝上）放入纱布袋内，纱布袋系以线绳，通过线绳将纱布袋固定于罐罐口，按每分钟温度下降1~2℃的速度，在40min内降至表面过夜，次晨投人中。3.传统程序：冷冻管置于4℃10分钟→-20℃30分钟→-80℃16~18小时（或隔夜）→槽长期储存。细胞冻存方法：1.预先配制冻存》（1）8%DMSO+细胞生长（92%血清）2.取对数生长期细胞，经胰酶消化后，加入适量冻存，用吸管吹打制成细胞悬（1×10(6)~5×10(6)细胞/ml）。3.加入1ml细胞于冻存管中，密封后标记冷冻细胞名称和冷冻日期。长期保存。保存细胞的复苏方法：1.快速解冻》冻存细胞从中取出后，立即放入37℃水浴中，轻轻摇动冷冻管，使其在1分钟内全部融化（不要超过3分钟）。2.解冻后的细胞可直接接种到含完全生长培养的细胞培养瓶中直接进行培养，24小时后再用新鲜完全培养替换旧培养，以去除DMSO。3.如果细胞对冷冻保护剂别敏感解冻后的细胞应先通过离心去除冷冻保护剂，然后再接种到含完全生长培养的培养瓶中。
SK-OV-3(luc)人卵巢癌细胞系
背景信息：详见相关文献介绍
┈订┈购┈热┈线：1┈5┈8┈0┈0┈5┈7┈6┈8┈6┈7【微信同号】┈Q┈Q：3┈3┈0┈7┈2┈0┈4┈2┈7┈1；
H-1944 Cells;背景说明：详见相关文献介绍;传代方法：１：３—１：６传代，每周换液２—３次;生长特性：贴壁生长;形态特性：上皮细胞样;相关产品有：SNB.19 Cells、H-35 Cells、Rat 2 Cells
Hs 737.T Cells;背景说明：详见相关文献介绍;传代方法：１：２—１：３传代；每周换液２-３次;生长特性：贴壁生长;形态特性：成纤维细胞;相关产品有：293 F Cells、BT Cells、Merwin Plasma Cell tumor-11 Cells
NCI-H1694 Cells;背景说明：详见相关文献介绍;传代方法：３-４天换液１次。;生长特性：悬浮生长;形态特性：聚团悬浮;相关产品有：H1048 Cells、OKAC1 Cells、NCI-H441 Cells
LCLC-103H Cells;背景说明：详见相关文献介绍;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁或悬浮，详见产品说明部分;形态特性：详见产品说明;相关产品有：Mouse Forestomach Carcinoma Cells、RPMI 7666 Cells、PA-TU-8988S Cells
产品包装：复苏发货：T25培养瓶(一瓶)或冻存发货：1ml冻存管(两支)
来源说明：细胞主要来源ATCC、ECACC、DSMZ、RIKEN等细胞库
SK-OV-3(luc)人卵巢癌细胞系
细胞冻存基本方法：１．细胞：选对数生长期细胞，收集细胞２４小时前换一次。２．计数：按常规方法把细胞制成细胞悬，计数，令细胞密度达５×１０(６)/ml，离心去上清，吸入离心管中。３．冻存：先用培养９分＋DMSO １分（或甘油）配成１０％的DMSO冻存，按上法一滴滴加入离心管中，然后用吸管轻轻吹打令细胞重悬。４．分装：分装入无菌安剖中，每安剖加１.５毫升细胞悬。５．封口：用塑料安剖时拧紧瓶口即可；如用火焰封闭安剖口后，仔细检查，定要封严，必要时可浸入蓝色中观察，为安全起见，把安剖缝入纱布小袋中，以防浸入后，融解时因受热发生爆炸伤人；纱袋一端系以线绳，末端扎有小牌，注明：细胞名称，冻存日期，以便日后查找。细胞株(系)的使用，为医学研究和测试工作带来了大的方便。但细胞的传代是有限制的，长期连续传代的细胞，不仅消耗大量的人力和物力，而且细胞的生长与形态等会有一定退变或转化，因而细胞失去原有的遗传性，有时还会由于细胞污染而造成传代中断，种子丢失。因此，在实际工作中常需冻存一定数量的细胞，以备替换使用。细胞冷冻与复苏是细胞培养 室的常规工作和通用技术。
NMC-G1 Cells;背景说明：详见相关文献介绍;传代方法：１：２传代;生长特性：贴壁生长;形态特性：上皮细胞;相关产品有：MB157 Cells、HLCL9B10 Cells、PanC1 Cells
H1944 Cells;背景说明：详见相关文献介绍;传代方法：１：３—１：６传代，每周换液２—３次;生长特性：贴壁生长;形态特性：上皮细胞样;相关产品有：Giant Cell Tumor Cells、HFF1 Cells、8505C Cells
SKNBE Cells;背景说明：１９７２年１１月从一们多次化疗及放疗的扩散性神经母细胞瘤患儿骨髓穿刺物中建立了SK-N-BE(２)神经母细胞瘤细胞株。 该细胞显示中等水平的多巴胺-β-羟基酶活性。 有报道称SK-N-BE(２)细胞的饱和浓度超过１x１０６细胞/平方厘米。细胞形态多样，有的有长突触，有的呈上皮细胞样。 细胞会聚集，形成团块并浮起;传代方法：１：２传代;生长特性：贴壁生长;形态特性：上皮细胞样;相关产品有：PZ-HPV-7 Cells、L-132 Cells、H-446 Cells
物种来源：人源、鼠源等其它物种来源
┈订┈购┈热┈线：1┈5┈8┈0┈0┈5┈7┈6┈8┈6┈7【微信同号】┈Q┈Q：3┈3┈0┈7┈2┈0┈4┈2┈7┈1；
形态特性：上皮细胞样
细胞培养无菌操作的演示：凡是带入超净工作台内的酒精、PBS、培养基、胰蛋白酶的瓶子均要用７５％酒精擦拭瓶子的外表面；靠近酒精灯火焰操作。器皿使用前必须过火灭菌，继续使用的器皿(如瓶盖、滴管)要放在GAO处，使用时仍要过火。各种操作要靠近酒精灯，动作要轻、准确，不能乱碰。如吸管不能碰到废缸。吸取两种以上的使用时要注意更换吸管，防止交叉污染。玻璃器械洗消：一、新的玻璃器皿的洗消：自来水刷洗，除去灰尘。烘干、泡：烤箱中烘干，然后再浸入５％稀中１２小时以除去脏物、铅、等物。刷洗、烘干：１２小时后立即用自来水冲洗，再用洗涤剂刷洗，自来水冲干净后用烤箱烘干；泡、清洗：用清洁浸泡１２小时，然后从缸内捞出器皿用自来水冲洗１５次，Zui后蒸馏水冲洗３-５次和用双蒸水过３次。烘干、包装：洗干净后先烘干，然后用牛皮纸(油光纸)包装。GAO压消毒：包装HAO的器皿装入GAO压锅内盖HAO盖子，打开开关和安全阀，当蒸气成直线上升时，关闭安全阀，当指针指向１５磅时，维持２０-３０分钟。GAO压消毒后烘干。二、旧的玻璃器皿的洗消：刷洗、烘干：使用过的玻璃器皿可直接泡入来苏尔或洗涤剂溶中，泡过来苏尔溶(洗涤剂)的器皿要用清水刷洗干净，然后烘干。泡、清洗：烘干后泡入清洁()，１２小时后从缸内捞出器皿立即用自来水冲洗(避免蛋白质干涸后粘附于玻璃上难以清洗)，再用蒸馏水冲洗３次。烘干、包装：洗干净的器皿烘干后取出用牛皮纸(油光纸)等包装。
C12 Cells;背景说明：该细胞株是YaffeD,SaxelO建立的小鼠成肌细胞系的亚株。该细胞分化较快，可形成能收缩的微管，产生特异的肌肉蛋白。在骨形态形成蛋白（BMP-２）的作用下，该细胞可由成肌细胞分化为成骨细胞。检测发现该细胞鼠痘病毒阴性。;传代方法：１：２传代;生长特性：贴壁生长;形态特性：成纤维细胞样；梭形;相关产品有：DLM8 Cells、TE13 Cells、RPMI-8226 Cells
HCC-1428 Cells;背景说明：详见相关文献介绍;传代方法：１：４-１：８传代；每周换液２-３次。;生长特性：贴壁生长，偶尔上皮细胞液泡的形成;形态特性：上皮细胞样;相关产品有：BNL-CL.2 Cells、HFL1 Cells、130-T Cells
Adeno 293 Cells;背景说明：详见相关文献介绍;传代方法：１：２传代;生长特性：贴壁生长;形态特性：详见产品说明;相关产品有：COLO-824 Cells、Hep-G2/C3A Cells、HCAEC Cells
NCIH650 Cells;背景说明：详见相关文献介绍;传代方法：１：３-１：６传代；;生长特性：悬浮生长;形态特性：球形的;相关产品有：K7M2 wt Cells、T 24 Cells、MDA-361 Cells
SHG44 Cells;背景说明：SHG-４４细胞株源自一例２-３级前沿淋巴结星细胞瘤。染色体组型显示８９.２%的超三倍体。在Wistar大鼠和裸鼠中接种都能成功。细胞含有神经系统特有的S-１００蛋白和星细胞特有的GFA蛋白;传代方法：消化３-５分钟。１：２。３天内可长满。;生长特性：贴壁生长;形态特性：成纤维细胞样;相关产品有：HEK293S Cells、SGC-7901/DDP Cells、T24(ECV304) Cells
SK-MEL5 Cells;背景说明：详见相关文献介绍;传代方法：１：３-１：６传代，２-３天换液１次。;生长特性：贴壁生长;形态特性：星形的;相关产品有：HemECs Cells、HUT-28 Cells、SW 403 Cells
VM Cub 1 Cells;背景说明：详见相关文献介绍;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁或悬浮，详见产品说明部分;形态特性：详见产品说明;相关产品有：INS1E Cells、HLEpiC Cells、22Rv1 Cells
KMS18 Cells;背景说明：浆细胞骨髓瘤；男性;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：半贴壁;形态特性：详见产品说明;相关产品有：NS20-Y Cells、UCLA NPA-87-1 Cells、JHH-7 Cells
Rabbit Kidney 13 Cells;背景说明：详见相关文献介绍;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁或悬浮，详见产品说明部分;形态特性：详见产品说明;相关产品有：NCIH1650 Cells、A2780CP70 Cells、SK-N-BE2C Cells
UWB1.289+BRCA1 Cells;背景说明：详见相关文献介绍;传代方法：１：２传代;生长特性：贴壁生长　;形态特性：详见产品说明;相关产品有：Capan 1 Cells、MDA-MB-435 Cells、SUM149 Cells
Tj-905 Cells;背景说明：胶质瘤;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁;形态特性：详见产品说明;相关产品有：GH 3 Cells、COLO678 Cells、mousepodocyte Cells
HCC-2108 Cells;背景说明：详见相关文献介绍;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁或悬浮，详见产品说明部分;形态特性：详见产品说明;相关产品有：Human Embryonic Skin Cells、N-9 Cells、KYSE-520 Cells
C22 Cells;背景说明：肺；上皮 Cells;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁;形态特性：详见产品说明;相关产品有：OVCAR 420 Cells、Ca759 Cells、NCIH1417 Cells
SNU5 Cells;背景说明：该细胞来源于一名低分化胃癌患者的转移性腹水，１９８７年分离建立。该细胞表达CEA和TAG-７２。;传代方法：２-３天补液一次。;生长特性：多细胞聚集、悬浮生长;形态特性：上皮细胞样;相关产品有：NCI-SNU-C2B Cells、Hela-Ap-1 Cells、HEK 293-EBNA Cells
KTA-7 Cells;背景说明：肺腺癌;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁;形态特性：详见产品说明;相关产品有：Y3-Ag 1.2.3 Cells、Colon-38 Cells、HOS Cells
SK-OV-3(luc)人卵巢癌细胞系
MM1 Cells;背景说明：急性单核细胞白血病；男性;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：悬浮;形态特性：详见产品说明;相关产品有：MV 4;11 Cells、Tregs Cells、NIH-3T3 Cells
NCIH1648 Cells;背景说明：详见相关文献介绍;传代方法：１：３-１：６传代;生长特性：贴壁生长;形态特性：上皮细胞;相关产品有：NRK-49F Cells、Hs343T Cells、NS-1 Cells
Abcam HCT 116 FOXP3 KO Cells(拥有STR基因鉴定图谱)
AG06562 Cells(拥有STR基因鉴定图谱)
BayGenomics ES cell line CSI656 Cells(拥有STR基因鉴定图谱)
BayGenomics ES cell line STA031 Cells(拥有STR基因鉴定图谱)
BIONi010-C-10 Cells(拥有STR基因鉴定图谱)
CIMHi001-A Cells(拥有STR基因鉴定图谱)
┈订┈购┈热┈线：1┈5┈8┈0┈0┈5┈7┈6┈8┈6┈7【微信同号】┈Q┈Q：3┈3┈0┈7┈2┈0┈4┈2┈7┈1；
DA03247 Cells(拥有STR基因鉴定图谱)
EL-4/cCD20 Cells(拥有STR基因鉴定图谱)
GM05758 Cells(拥有STR基因鉴定图谱)
H2405 Cells;背景说明：详见相关文献介绍;传代方法：１：５-１：８传代;生长特性：混合生长;形态特性：详见产品说明;相关产品有：BALL-1 Cells、C3H/10T1/2 CL8 Cells、P3 NS1 Ag4 Cells
QBI-HEK 293A Cells;背景说明：胚肾；腺病毒包装;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁;形态特性：详见产品说明;相关产品有：EU-2 Cells、MN9D Cells、CHAGOK1 Cells
ONS-76 Cells;背景说明：详见相关文献介绍;传代方法：１：２传代;生长特性：贴壁生长;形态特性：上皮样;相关产品有：3D4/21 Cells、SC Cells、KRC Y Cells
SK-MEL2 Cells;背景说明：详见相关文献介绍;传代方法：１：３-１：６传代，２-３天换液１次。;生长特性：贴壁生长;形态特性：多边形的;相关产品有：COLO824 Cells、NCIH2286 Cells、NBL-2 Cells
H-2196 Cells;背景说明：详见相关文献介绍;传代方法：１：３-１：６传代；每周换液２次。;生长特性：贴壁或悬浮，详见产品说明部分;形态特性：详见产品说明;相关产品有：HTori 3 Cells、PANC3.27 Cells、C1R Cells
H250 Cells;背景说明：小细胞肺癌；男性;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：半贴壁;形态特性：详见产品说明;相关产品有：VM-CUB1 Cells、RERF-LC-MS Cells、NU-GC-2 Cells
RTE Cells;背景说明：详见相关文献介绍;传代方法：１：３传代，３-４天换液一次;生长特性：贴壁生长;形态特性：多角;相关产品有：ECC-1 Cells、UACC 893 Cells、H-250 Cells
MCF-7B Cells;背景说明：浸润性导管癌；胸腔积液转移；女性;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁;形态特性：详见产品说明;相关产品有：Jurkat E6.1 Cells、TFK-1 Cells、NCIH1703 Cells
CA 46 Cells;背景说明：该细胞源自Burkitt＇s淋巴瘤患者的B淋巴细胞，EBNA、Fc阴性。;传代方法：１：２传代;生长特性：悬浮生长;形态特性：淋巴母细胞样;相关产品有：D283 Med Cells、WERI-Rb 1 Cells、Colo741 Cells
CC-LP-1 Cells;背景说明：详见相关文献介绍;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁或悬浮，详见产品说明部分;形态特性：详见产品说明;相关产品有：HCC-2279 Cells、TE-11 Cells、HEC1B Cells
SNU-601 Cells;背景说明：详见相关文献介绍;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁或悬浮，详见产品说明部分;形态特性：详见产品说明;相关产品有：NT2/D1 Cells、PANC-03-27 Cells、DSL-6A-C1 Cells
SUM190 Cells;背景说明：乳腺癌；女性;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁;形态特性：详见产品说明;相关产品有：SW 780 Cells、JURKAT E-61 Cells、SCC15 Cells
Hs819T Cells;背景说明：详见相关文献介绍;传代方法：１：２—１：３传代；每周换液２-３次;生长特性：贴壁生长;形态特性：成纤维;相关产品有：HS-766-T Cells、U2OS Cells、INS1-E Cells
A9(Neo11) Cells(拥有STR基因鉴定图谱)
TE-11 Cells;背景说明：详见相关文献介绍;传代方法：消化３-５分钟。１：２。３天内可长满。;生长特性：贴壁生长;形态特性：上皮样;相关产品有：HuPT4 Cells、COV434 Cells、RPMI6666 Cells
OCI AML2 Cells;背景说明：急性髓系白血病；男性;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：悬浮;形态特性：详见产品说明;相关产品有：MKN-45 Cells、SUNE1 Cells、GM00346B Cells
BHT-101 Cells;背景说明：甲状腺癌；女性;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁;形态特性：详见产品说明;相关产品有：MSTO211H Cells、DV-90 Cells、JeKo 1 Cells
SKNBE-2 Cells;背景说明：１９７２年１１月从一们多次化疗及放疗的扩散性神经母细胞瘤患儿骨髓穿刺物中建立了SK-N-BE(２)神经母细胞瘤细胞株。 该细胞显示中等水平的多巴胺-β-羟基酶活性。 有报道称SK-N-BE(２)细胞的饱和浓度超过１x１０６细胞/平方厘米。细胞形态多样，有的有长突触，有的呈上皮细胞样。 细胞会聚集，形成团块并浮起;传代方法：１：２传代;生长特性：贴壁生长;形态特性：上皮细胞样;相关产品有：Laboratory of Allergic Diseases 2 Cells、IMCD3 Cells、SCL I Cells
HeLa/S3 Cells;背景说明：该细胞是１９５５年由PuckTT,MarcusPI和CieciuraSJ建系的，含HPV-１８序列；角蛋白阳性；可用于与染色体突变、细胞营养、集落形成相关的哺乳动物细胞的克隆分析。;传代方法：１：２传代;生长特性：贴壁生长;形态特性：上皮样;相关产品有：Lilly Laboratories Cell-Porcine Kidney 1 Cells、NCTC1469 Cells、GP-293 Cells
Meat Animal Research Center-145 Cells;背景说明：胚肾；自发永生;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁;形态特性：详见产品说明;相关产品有：Hu-P-T3 Cells、CWR22R Cells、CCD-841-CoN Cells
SNU-1 Cells;背景说明：详见相关文献介绍;传代方法：２-３天换液１次。;生长特性：悬浮聚集;形态特性：上皮细胞;相关产品有：MDA436 Cells、U-138MG Cells、U373-MG Cells
MDA-MB-175VII Cells;背景说明：该细胞源自一位５４岁患有乳腺导管癌白人女性的胸腔积液。;传代方法：１：２—１：６传代，每周换液２—３次;生长特性：松散贴壁生长;形态特性：上皮细胞样;相关产品有：H-2108 Cells、SF767 Cells、BNL-HCC Cells
GM12620 Cells(拥有STR基因鉴定图谱)
HAP1 ERCC5 (-) 2 Cells(拥有STR基因鉴定图谱)
A-375 Cells;背景说明：A３７５源自一位５４岁女性，是Giard DJ等人建立的一系列细胞株中的一株。该细胞可在免疫抑制小鼠上成瘤，在琼脂上形成克隆。;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁;形态特性：上皮细胞样;相关产品有：H647ell Cells、A.704 Cells、Hs683T Cells
HiPS-RIKEN-4C Cells(拥有STR基因鉴定图谱)
IPS(Foreskin)-4 Cells(拥有STR基因鉴定图谱)
MBA-2.4 Cells(拥有STR基因鉴定图谱)
ND10686 Cells(拥有STR基因鉴定图谱)
PL26 Cells(拥有STR基因鉴定图谱)
TSCC-1 Cells(拥有STR基因鉴定图谱)
UL-1 [Dog leukemia] Cells(拥有STR基因鉴定图谱)
HCT116-UNC93B1-KO-c20 Cells(拥有STR基因鉴定图谱)
H-2108 Cells;背景说明：详见相关文献介绍;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁或悬浮，详见产品说明部分;形态特性：详见产品说明;相关产品有：HEK;293 Cells、KM932 Cells、HS578 Cells
Centre Antoine Lacassagne-62 Cells;背景说明：详见相关文献介绍;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁或悬浮，详见产品说明部分;形态特性：详见产品说明;相关产品有：MESSA Cells、IHC-ST1 Cells、CEM-CCRF (CAMR) Cells
VMM5A Cells;背景说明：黑色素瘤；神经节转移；男性;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁;形态特性：详见产品说明;相关产品有：CX-1 Cells、Fox/NY Cells、7860 Cells
NCI-H1437 Cells;背景说明：详见相关文献介绍;传代方法：１：２-１：６传代,每周换液２次。;生长特性：贴壁生长;形态特性：上皮样;相关产品有：H2141 Cells、MV 3 Cells、KBM-7/Hap8 Cells
NCIH747 Cells;背景说明：详见相关文献介绍;传代方法：１：２—１：４传代，每周换液２次;生长特性：贴壁生长;形态特性：上皮样;相关产品有：SK Mel 1 Cells、RFL-6 Cells、U266BL Cells
NCIH747 Cells;背景说明：详见相关文献介绍;传代方法：１：２—１：４传代，每周换液２次;生长特性：贴壁生长;形态特性：上皮样;相关产品有：SK Mel 1 Cells、RFL-6 Cells、U266BL Cells
HCC-1954 Cells;背景说明：详见相关文献介绍;传代方法：１：４-１：８传代；每周换液２-３次。;生长特性：偶尔上皮细胞空泡;形态特性：上皮细胞样;相关产品有：CMECs Cells、P3-X63Ag8 Cells、EST50 Cells
BE2-M17 Cells;背景说明：详见相关文献介绍;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁或悬浮，详见产品说明部分;形态特性：详见产品说明;相关产品有：COLO680N Cells、CDC/EU.HMEC-1 Cells、SW1222 Cells
38C13 Cells;背景说明：B淋巴瘤；C３H/eB;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：半贴壁;形态特性：详见产品说明;相关产品有：YH Cells、P31-FUJ Cells、Tn5 B1-4 Cells
NCIH747 Cells;背景说明：详见相关文献介绍;传代方法：１：２—１：４传代，每周换液２次;生长特性：贴壁生长;形态特性：上皮样;相关产品有：SK Mel 1 Cells、RFL-6 Cells、U266BL Cells
NCI-H847 Cells;背景说明：详见相关文献介绍;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁或悬浮，详见产品说明部分;形态特性：详见产品说明;相关产品有：Namalwa Cells、NCI-H-128 Cells、IPLB-SF 21AE Cells
NCIN87 Cells;背景说明：NCI-N８７细胞表达表面糖蛋白癌胚抗原(CEA)和TAG７２,并且没有左旋多巴胺脱羧酶(DDC)活性。它们的血管活性的肠肽(VIP)受体活性极低并缺乏胃泌激素受体。它们表达蕈毒碱胆碱受体。没有证据表明存在N-myc,L-myc,myb和EGF受体基因的重组。这个细胞株表达的c-myc和c-erb-B２RNA水平与其它细胞株相当。以下基因不表达:N-myc,L-myc,c-cis,IGF-２,或胃泌激素释放肽。报道NCI-N８７细胞的植板率为４.３%。;传代方法：消化１５-２０分钟。１：２。４-５天长满。;生长特性：贴壁生长;形态特性：上皮细胞样;相关产品有：H1876 Cells、NCIH841 Cells、NCI-H2405 Cells
K 562 Cells;背景说明：详见相关文献介绍;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁或悬浮，详见产品说明部分;形态特性：详见产品说明;相关产品有：Walker/LLC-WRC 256 Cells、RPMI2650 Cells、H-1568 Cells
H-4-II-E Cells;背景说明：详见相关文献介绍;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁或悬浮，详见产品说明部分;形态特性：详见产品说明;相关产品有：8505C Cells、SNUC2A Cells、U-373-MG Cells
C3H 10T1/2 Cells;背景说明：详见相关文献介绍;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁或悬浮，详见产品说明部分;形态特性：详见产品说明;相关产品有：CA 46 Cells、H2126 Cells、HCC44 Cells
SGC-7901/B2 Cells(拥有STR基因鉴定图谱)
SHG-44 Cells;背景说明：SHG-４４细胞株源自一例２-３级前沿淋巴结星细胞瘤。染色体组型显示８９.２%的超三倍体。在Wistar大鼠和裸鼠中接种都能成功。细胞含有神经系统特有的S-１００蛋白和星细胞特有的GFA蛋白;传代方法：消化３-５分钟。１：２。３天内可长满。;生长特性：贴壁生长;形态特性：成纤维细胞样;相关产品有：H4 Cells、A253 Cells、SF295 Cells
X63-Ag8 Cells;背景说明：详见相关文献介绍;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁或悬浮，详见产品说明部分;形态特性：详见产品说明;相关产品有：H187 Cells、SW 1783 Cells、H1930 Cells
SNU484 Cells;背景说明：详见相关文献介绍;传代方法：１：２传代;生长特性：贴壁或悬浮，详见产品说明部分;形态特性：详见产品说明;相关产品有：Hs819T Cells、NCIH64 Cells、OV-2008 Cells
GLC82 Cells;背景说明：详见相关文献介绍;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁或悬浮，详见产品说明部分;形态特性：详见产品说明;相关产品有：NCTC 929 Cells、Panc5.04 Cells、TE-8 Cells
SKGT2 Cells;背景说明：胃底癌；男性;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁;形态特性：详见产品说明;相关产品有：Hs 895 T Cells、SK LU 1 Cells、TE 32 Cells
H2196 Cells;背景说明：详见相关文献介绍;传代方法：１：３-１：６传代；每周换液２次。;生长特性：贴壁或悬浮，详见产品说明部分;形态特性：详见产品说明;相关产品有：LA-N-6(OAN) Cells、MC/CAR Cells、IGR-OV1 Cells
┈订┈购┈热┈线：1┈5┈8┈0┈0┈5┈7┈6┈8┈6┈7【微信同号】┈Q┈Q：3┈3┈0┈7┈2┈0┈4┈2┈7┈1；
TE32 Cells;背景说明：详见相关文献介绍;传代方法：１：２-１：４传代，３-４天换液１次。;生长特性：贴壁生长;形态特性：梭型和大的多核细胞;相关产品有：NIH-3T3 Cells、LC1-Sq Cells、MDA-MB-415 Cells
HCC94 Cells;背景说明：详见相关文献介绍;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁或悬浮，详见产品说明部分;形态特性：详见产品说明;相关产品有：HCC-2218 Cells、AN-3 Cells、H2227 Cells
NCI-H209 Cells;背景说明：详见相关文献介绍;传代方法：１：２-１：４传代；每周换液２次。;生长特性：悬浮生长，有少数细胞疏松贴壁;形态特性：上皮样;相关产品有：RA.1 Cells、H1693 Cells、KBM-7 Cells
NCI-SNU-423 Cells;背景说明：详见相关文献介绍;传代方法：１：２传代;生长特性：贴壁生长;形态特性：上皮样;相关产品有：CNE2 Cells、H2085 Cells、MAVER1 Cells
YES2 Cells;背景说明：食管鳞癌；男性;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁;形态特性：详见产品说明;相关产品有：MDAMB175 Cells、M210B4 Cells、RPMI 8402 Cells
BJA-B-1 Cells;背景说明：Burkitt's淋巴瘤;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：悬浮;形态特性：详见产品说明;相关产品有：GES1 Cells、MDBK Cells、CCLP-1 Cells
KOSC2 Cells;背景说明：详见相关文献介绍;传代方法：２.２ x １０^４ cells/ml ;生长特性：贴壁生长;形态特性：上皮样;相关产品有：C-Lu65 Cells、ZR75_1 Cells、HCC9724 Cells
SK-OV-3(luc)人卵巢癌细胞系
CEF Cells;背景说明：胚胎；成纤维 Cells;传代方法：１：２-１：３传代；每周换液２-３次。;生长特性：贴壁;形态特性：详见产品说明;相关产品有：CCRF.CEM Cells、DoHH-2 Cells、LTEP a2 Cells
BayGenomics ES cell line RRJ416 Cells(拥有STR基因鉴定图谱)
BayGenomics ES cell line XK392 Cells(拥有STR基因鉴定图谱)
FR10B4 Cells(拥有STR基因鉴定图谱)
NQ2.21.2 Cells(拥有STR基因鉴定图谱)
WU E-14 Cells(拥有STR基因鉴定图谱)
MCF10A_STAG2_9 Cells(拥有STR基因鉴定图谱)
"    "PubMed=1000506
Lippman M.E., Bolan G., Huff K.
The effects of androgens and antiandrogens on hormone-responsive human breast cancer in long-term tissue culture.
Cancer Res. 36:4610-4618(1976)

PubMed=833871; DOI=10.1093/jnci/58.2.209
Fogh J., Wright W.C., Loveless J.D.
Absence of HeLa cell contamination in 169 cell lines derived from human tumors.
J. Natl. Cancer Inst. 58:209-214(1977)

PubMed=77569; DOI=10.1111/j.1399-0039.1978.tb01259.x
Espmark J.A., Ahlqvist-Roth L., Sarne L., Persson A.
Tissue typing of cells in culture. III. HLA antigens of established human cell lines. Attempts at typing by the mixed hemadsorption technique.
Tissue Antigens 11:279-286(1978)

PubMed=730202; DOI=10.1007/BF02616120
Cailleau R.M., Olive M., Cruciger Q.V.J.
Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization.
In Vitro 14:911-915(1978)

PubMed=7000337
Brinkley B.R., Beall P.T., Wible L.J., Mace M.L. Jr., Turner D.S., Cailleau R.M.
Variations in cell form and cytoskeleton in human breast carcinoma cells in vitro.
Cancer Res. 40:3118-3129(1980)

PubMed=6935474; DOI=10.1093/jnci/66.2.239
Wright W.C., Daniels W.P., Fogh J.
Distinction of seventy-one cultured human tumor cell lines by polymorphic enzyme analysis.
J. Natl. Cancer Inst. 66:239-247(1981)

PubMed=7272986; DOI=10.1016/0165-4608(81)90057-1
Satya-Prakash K.L., Pathak S., Hsu T.-C., Olive M., Cailleau R.M.
Cytogenetic analysis on eight human breast tumor cell lines: high frequencies of 1q, 11q and HeLa-like marker chromosomes.
Cancer Genet. Cytogenet. 3:61-73(1981)

PubMed=7459858
Rousset M., Zweibaum A., Fogh J.
Presence of glycogen and growth-related variations in 58 cultured human tumor cell lines of various tissue origins.
Cancer Res. 41:1165-1170(1981)

PubMed=6582512; DOI=10.1073/pnas.81.2.568; PMCID=PMC344720
Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.
Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.
Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984)

PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

PubMed=3335022
Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.
Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.
Cancer Res. 48:589-601(1988)

PubMed=1961733; DOI=10.1073/pnas.88.23.10657; PMCID=PMC52989
Runnebaum I.B., Nagarajan M., Bowman M., Soto D., Sukumar S.
Mutations in p53 as potential molecular markers for human breast cancer.
Proc. Natl. Acad. Sci. U.S.A. 88:10657-10661(1991)

PubMed=7902062
de la Torre M., Hao X.-Y., Larsson R., Nygren P., Tsuruo T., Mannervik B., Bergh J.
Characterization of four doxorubicin adapted human breast cancer cell lines with respect to chemotherapeutic drug sensitivity, drug resistance associated membrane proteins and glutathione transferases.
Anticancer Res. 13:1425-1430(1993)

DOI=10.1016/B978-0-12-333530-2.50009-5
Leibovitz A.
Cell lines from human breast.
(In book chapter) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.161-184; Academic Press; New York; USA (1994)

PubMed=8824553; DOI=10.1002/(SICI)1097-0215(19960917)67:6<816::AID-IJC10>3.0.CO;2-#
Mullen P., Ritchie A., Langdon S.P., Miller W.R.
Effect of Matrigel on the tumorigenicity of human breast and ovarian carcinoma cell lines.
Int. J. Cancer 67:816-820(1996)

PubMed=9815641
Wosikowski K., Schuurhuis D.H., Kops G.J.P.L., Saceda M., Bates S.E.
Altered gene expression in drug-resistant human breast cancer cells.
Clin. Cancer Res. 3:2405-2414(1997)

PubMed=9670966; DOI=10.4049/jimmunol.161.2.877
Bettinotti M.P., Kim C.J., Lee K.-H., Roden M., Cormier J.N., Panelli M.C., Parker K.K., Marincola F.M.
Stringent allele/epitope requirements for MART-1/Melan A immunodominance: implications for peptide-based immunotherapy.
J. Immunol. 161:877-889(1998)

PubMed=9671407; DOI=10.1038/sj.onc.1201814
Sweeney K.J., Swarbrick A., Sutherland R.L., Musgrove E.A.
Lack of relationship between CDK activity and G1 cyclin expression in breast cancer cells.
Oncogene 16:2865-2878(1998)

PubMed=10700174; DOI=10.1038/73432
Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T., Iyer V.R., Jeffrey S.S., van de Rijn M., Waltham M.C., Pergamenschikov A., Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., Brown P.O.
Systematic variation in gene expression patterns in human cancer cell lines.
Nat. Genet. 24:227-235(2000)

PubMed=10969801
Forozan F., Mahlamaki E.H., Monni O., Chen Y.-D., Veldman R., Jiang Y., Gooden G.C., Ethier S.P., Kallioniemi A.H., Kallioniemi O.-P.
Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data.
Cancer Res. 60:4519-4525(2000)

PubMed=11499871; DOI=10.1359/jbmr.2001.16.8.1486
Yoneda T., Williams P.J., Hiraga T., Niewolna M., Nishimura R.
A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro.
J. Bone Miner. Res. 16:1486-1495(2001)

PubMed=11687795; DOI=10.1038/ng754
Snijders A.M., Nowak N.J., Segraves R., Blackwood S., Brown N., Conroy J., Hamilton G., Hindle A.K., Huey B., Kimura K., Law S., Myambo K., Palmer J., Ylstra B., Yue J.P., Gray J.W., Jain A.N., Pinkel D., Albertson D.G.
Assembly of microarrays for genome-wide measurement of DNA copy number.
Nat. Genet. 29:263-264(2001)

PubMed=11697798; DOI=10.1359/jbmr.2001.16.11.2027
Peyruchaud O., Winding B., Pecheur I., Serre C.-M., Delmas P., Clezardin P.
Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions.
J. Bone Miner. Res. 16:2027-2034(2001)

PubMed=12068308; DOI=10.1038/nature00766
Davies H.R., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S., Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S., Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.
Mutations of the BRAF gene in human cancer.
Nature 417:949-954(2002)

PubMed=12353263; DOI=10.1002/gcc.10107
Popovici C., Basset C., Bertucci F., Orsetti B., Adelaide J., Mozziconacci M.-J., Conte N., Murati A., Ginestier C., Charafe-Jauffret E., Ethier S.P., Lafage-Pochitaloff M., Theillet C., Birnbaum D., Chaffanet M.
Reciprocal translocations in breast tumor cell lines: cloning of a t(3;20) that targets the FHIT gene.
Genes Chromosomes Cancer 35:204-218(2002)

PubMed=12661003; DOI=10.1002/gcc.10196
Seitz S., Wassmuth P., Plaschke J., Schackert H.K., Karsten U., Santibanez-Koref M.F., Schlag P.M., Scherneck S.
Identification of microsatellite instability and mismatch repair gene mutations in breast cancer cell lines.
Genes Chromosomes Cancer 37:29-35(2003)

PubMed=12800145; DOI=10.1002/gcc.10218
Adelaide J., Huang H.-E., Murati A., Alsop A.E., Orsetti B., Mozziconacci M.-J., Popovici C., Ginestier C., Letessier A., Basset C., Courtay-Cahen C., Jacquemier J., Theillet C., Birnbaum D., Edwards P.A.W., Chaffanet M.
A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 gene.
Genes Chromosomes Cancer 37:333-345(2003)

PubMed=15153330; DOI=10.1593/neo.3292; PMCID=PMC1502105
Watts G.S., Oshiro M.M., Junk D.J., Wozniak R.J., Watterson S.J., Domann F.E., Futscher B.W.
The acetyltransferase p300/CBP-associated factor is a p53 target gene in breast tumor cells.
Neoplasia 6:187-194(2004)

PubMed=15677628; DOI=10.1093/carcin/bgi032
Gorringe K.L., Chin S.-F., Pharoah P.D.P., Staines J.M., Oliveira C., Edwards P.A.W., Caldas C.
Evidence that both genetic instability and selection contribute to the accumulation of chromosome alterations in cancer.
Carcinogenesis 26:923-930(2005)

PubMed=15748285; DOI=10.1186/1479-5876-3-11; PMCID=PMC555742
Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L., Morse H.C. 3rd, Stroncek D., Marincola F.M.
HLA class I and II genotype of the NCI-60 cell lines.
J. Transl. Med. 3:11.1-11.8(2005)

PubMed=15767549; DOI=10.1158/1535-7163.MCT-04-0234
Nakatsu N., Yoshida Y., Yamazaki K., Nakamura T., Dan S., Fukui Y., Yamori T.
Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays.
Mol. Cancer Ther. 4:399-412(2005)

PubMed=15900046; DOI=10.1093/jnci/dji133
Mashima T., Oh-hara T., Sato S., Mochizuki M., Sugimoto Y., Yamazaki K., Hamada J.-i., Tada M., Moriuchi T., Ishikawa Y., Kato Y., Tomoda H., Yamori T., Tsuruo T.
p53-defective tumors with a functional apoptosome-mediated pathway: a new therapeutic target.
J. Natl. Cancer Inst. 97:765-777(2005)

PubMed=16049480; DOI=10.1038/nature03799; PMCID=PMC1283098
Minn A.J., Gupta G.P., Siegel P.M., Bos P.D., Shu W.-P., Giri D.D., Viale A.J., Olshen A.B., Gerald W.L., Massague J.
Genes that mediate breast cancer metastasis to lung.
Nature 436:518-524(2005)

PubMed=16142302; DOI=10.3892/ijo.27.4.881
de Longueville F., Lacroix M., Barbuto A.-M., Bertholet V., Gallo D., Larsimont D., Marcq L., Zammatteo N., Boffe S., Leclercq G., Remacle J.
Molecular characterization of breast cancer cell lines by a low-density microarray.
Int. J. Oncol. 27:881-892(2005)

PubMed=16397213; DOI=10.1158/0008-5472.CAN-05-2853
Elstrodt F., Hollestelle A., Nagel J.H.A., Gorin M., Wasielewski M., van den Ouweland A.M.W., Merajver S.D., Ethier S.P., Schutte M.
BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants.
Cancer Res. 66:41-45(2006)

PubMed=16417655; DOI=10.1186/bcr1370; PMCID=PMC1413994
Shadeo A., Lam W.L.
Comprehensive copy number profiles of breast cancer cell model genomes.
Breast Cancer Res. 8:R9.1-R9.14(2006)

PubMed=16541312; DOI=10.1007/s10549-006-9186-z
Wasielewski M., Elstrodt F., Klijn J.G.M., Berns E.M.J.J., Schutte M.
Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines.
Breast Cancer Res. Treat. 99:97-101(2006)

PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433; PMCID=PMC2705832
Ikediobi O.N., Davies H.R., Bignell G.R., Edkins S., Stevens C., O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L., Buck G., Butler A.P., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C., Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A., Miroo T., Parker A., Perry J., Raine K.M., Richardson D., Shepherd R., Small A., Smith R., Solomon H., Stephens P.J., Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.
Mol. Cancer Ther. 5:2606-2612(2006)

PubMed=17157791; DOI=10.1016/j.ccr.2006.10.008; PMCID=PMC2730521
Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T., Clark L., Bayani N., Coppe J.-P., Tong F., Speed T., Spellman P.T., DeVries S., Lapuk A., Wang N.J., Kuo W.-L., Stilwell J.L., Pinkel D., Albertson D.G., Waldman F.M., McCormick F., Dickson R.B., Johnson M.D., Lippman M.E., Ethier S.P., Gazdar A.F., Gray J.W.
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.
Cancer Cell 10:515-527(2006)

PubMed=17334996; DOI=10.1002/gcc.20438
Jonsson G., Staaf J., Olsson E., Heidenblad M., Vallon-Christersson J., Osoegawa K., de Jong P.J., Oredsson S.M., Ringner M., Hoglund M., Borg A.
High-resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization.
Genes Chromosomes Cancer 46:543-558(2007)

PubMed=18516279; DOI=10.1016/j.molonc.2007.02.004; PMCID=PMC2391005
Kenny P.A., Lee G.Y., Myers C.A., Neve R.M., Semeiks J.R., Spellman P.T., Lorenz K., Lee E.H., Barcellos-Hoff M.H., Petersen O.W., Gray J.W., Bissell M.J.
The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression.
Mol. Oncol. 1:84-96(2007)

PubMed=18277095; DOI=10.4161/cbt.7.5.5712
Berglind H., Pawitan Y., Kato S., Ishioka C., Soussi T.
Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination.
Cancer Biol. Ther. 7:699-708(2008)

PubMed=18386134; DOI=10.1007/s10585-008-9169-z
Hughes L., Malone C., Chumsri S., Burger A.M., McDonnell S.
Characterisation of breast cancer cell lines and establishment of a novel isogenic subclone to study migration, invasion and tumourigenicity.
Clin. Exp. Metastasis 25:549-557(2008)

PubMed=18714363; DOI=10.1593/neo.08570; PMCID=PMC2517647
Kischel P., Guillonneau F., Dumont B., Bellahcene A., Stresing V., Clezardin P., De Pauw E.A., Castronovo V.
Cell membrane proteomic analysis identifies proteins differentially expressed in osteotropic human breast cancer cells.
Neoplasia 10:1014-1020(2008)

PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921; PMCID=PMC4020356
Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y., Chanock S.J., Weinstein J.N.
DNA fingerprinting of the NCI-60 cell line panel.
Mol. Cancer Ther. 8:713-724(2009)

PubMed=19582160; DOI=10.1371/journal.pone.0006146; PMCID=PMC2702084
Kao J., Salari K., Bocanegra M., Choi Y.-L., Girard L., Gandhi J., Kwei K.A., Hernandez-Boussard T., Wang P., Gazdar A.F., Minna J.D., Pollack J.R.
Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.
PLoS ONE 4:E6146-E6146(2009)

DOI=10.25904/1912/1434
Morrison B.J.
Breast cancer stem cells: tumourspheres and implications for therapy.
Thesis PhD (2010); Griffith University; Brisbane; Australia

PubMed=19593635; DOI=10.1007/s10549-009-0460-8
Hollestelle A., Nagel J.H.A., Smid M., Lam S., Elstrodt F., Wasielewski M., Ng S.S., French P.J., Peeters J.K., Rozendaal M.J., Riaz M., Koopman D.G., ten Hagen T.L.M., de Leeuw B.H.C.G.M., Zwarthoff E.C., Teunisse A.F.A.S., van der Spek P.J., Klijn J.G.M., Dinjens W.N.M., Ethier S.P., Clevers H.C., Jochemsen A.G., den Bakker M.A., Foekens J.A., Martens J.W.M., Schutte M.
Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines.
Breast Cancer Res. Treat. 121:53-64(2010)

PubMed=20070913; DOI=10.1186/1471-2407-10-15; PMCID=PMC2836299
Tsuji K., Kawauchi S., Saito S., Furuya T., Ikemoto K., Nakao M., Yamamoto S., Oka M., Hirano T., Sasaki K.
Breast cancer cell lines carry cell line-specific genomic alterations that are distinct from aberrations in breast cancer tissues: comparison of the CGH profiles between cancer cell lines and primary cancer tissues.
BMC Cancer 10:15.1-15.10(2010)

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113
Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=21778573; DOI=10.3233/BD-2010-0307; PMCID=PMC3532890
Chavez K.J., Garimella S.V., Lipkowitz S.
Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer.
Breast Dis. 32:35-48(2010)

DOI=10.4172/2157-7145.S2-005
Fang R.-X., Shewale J.G., Nguyen V.T., Cardoso H., Swerdel M.R., Hart R.P., Furtado M.R.
STR profiling of human cell lines: challenges and possible solutions to the growing problem.
J. Forensic Res. 2 Suppl. 2:5-5(2011)

PubMed=21378333
Ford C.H.J., Al-Bader M., Al-Ayadhi B., Francis I.
Reassessment of estrogen receptor expression in human breast cancer cell lines.
Anticancer Res. 31:521-527(2011)

PubMed=22068913; DOI=10.1073/pnas.1111840108; PMCID=PMC3219108
Gillet J.-P., Calcagno A.M., Varma S., Marino M., Green L.J., Vora M.I., Patel C., Orina J.N., Eliseeva T.A., Singal V., Padmanabhan R., Davidson B., Ganapathi R., Sood A.K., Rueda B.R., Ambudkar S.V., Gottesman M.M.
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.
Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011)

PubMed=22336246; DOI=10.1016/j.bmc.2012.01.017
Kong D.-X., Yamori T.
JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
Bioorg. Med. Chem. 20:1947-1951(2012)

PubMed=22347499; DOI=10.1371/journal.pone.0031628; PMCID=PMC3276511
Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C.
Mass homozygotes accumulation in the NCI-60 cancer cell lines as compared to HapMap trios, and relation to fragile site location.
PLoS ONE 7:E31628-E31628(2012)

PubMed=22384151; DOI=10.1371/journal.pone.0032096; PMCID=PMC3285665
Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H., Yoon C.N., Chang Y.-T.
Identification of cancer cell-line origins using fluorescence image-based phenomic screening.
PLoS ONE 7:E32096-E32096(2012)

PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=22585861; DOI=10.1158/2159-8290.CD-11-0224; PMCID=PMC5057396
Marcotte R., Brown K.R., Suarez Saiz F.J., Sayad A., Karamboulas K., Krzyzanowski P.M., Sircoulomb F., Medrano M., Fedyshyn Y., Koh J.L.-Y., van Dyk D., Fedyshyn B., Luhova M., Brito G.C., Vizeacoumar F.J., Vizeacoumar F.S., Datti A., Kasimer D., Buzina A., Mero P., Misquitta C., Normand J., Haider M., Ketela T., Wrana J.L., Rottapel R., Neel B.G., Moffat J.
Essential gene profiles in breast, pancreatic, and ovarian cancer cells.
Cancer Discov. 2:172-189(2012)

PubMed=22628656; DOI=10.1126/science.1218595; PMCID=PMC3526189
Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L., Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.
Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation.
Science 336:1040-1044(2012)

PubMed=23151021; DOI=10.1186/1471-2164-13-619; PMCID=PMC3546428
Grigoriadis A., Mackay A., Noel E., Wu P.-J., Natrajan R., Frankum J., Reis-Filho J.S., Tutt A.
Molecular characterisation of cell line models for triple-negative breast cancers.
BMC Genomics 13:619.1-619.14(2012)

PubMed=23601657; DOI=10.1186/bcr3415; PMCID=PMC3672661
Riaz M., van Jaarsveld M.T.M., Hollestelle A., Prager-van der Smissen W.J.C., Heine A.A.J., Boersma A.W.M., Liu J.-J., Helmijr J.C.A., Ozturk B., Smid M., Wiemer E.A.C., Foekens J.A., Martens J.W.M.
miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs.
Breast Cancer Res. 15:R33.1-R33.17(2013)

PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342; PMCID=PMC4893961
Abaan O.D., Polley E.C., Davis S.R., Zhu Y.-L.J., Bilke S., Walker R.L., Pineda M.A., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L., Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.
The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.
Cancer Res. 73:4372-4382(2013)

PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018
Moghaddas Gholami A., Hahne H., Wu Z.-X., Auer F.J., Meng C., Wilhelm M., Kuster B.
Global proteome analysis of the NCI-60 cell line panel.
Cell Rep. 4:609-620(2013)

PubMed=24009699; DOI=10.1371/journal.pone.0072704; PMCID=PMC3751845
Liu X., Nie H., Zhang Y.-B., Yao Y.-F., Maitikabili A., Qu Y.-P., Shi S.-L., Chen C.-Y., Li Y.
Cell surface-specific N-glycan profiling in breast cancer.
PLoS ONE 8:E72704-E72704(2013)

PubMed=24094812; DOI=10.1016/j.ccr.2013.08.020; PMCID=PMC3931310
Timmerman L.A., Holton T., Yuneva M., Louie R.J., Padro M., Daemen A., Hu M., Chan D.A., Ethier S.P., van 't Veer L.J., Polyak K., McCormick F., Gray J.W.
Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target.
Cancer Cell 24:450-465(2013)

PubMed=24162158; DOI=10.1007/s10549-013-2743-3; PMCID=PMC3832776
Prat A., Karginova O., Parker J.S., Fan C., He X.-P., Bixby L.M., Harrell J.C., Roman E., Adamo B., Troester M.A., Perou C.M.
Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes.
Breast Cancer Res. Treat. 142:237-255(2013)

PubMed=24176112; DOI=10.1186/gb-2013-14-10-r110; PMCID=PMC3937590
Daemen A., Griffith O.L., Heiser L.M., Wang N.J., Enache O.M., Sanborn Z., Pepin F., Durinck S., Korkola J.E., Griffith M., Hur J.S., Huh N., Chung J., Cope L., Fackler M.J., Umbricht C.B., Sukumar S., Seth P., Sume V.P., Jakkula L.R., Lu Y.-L., Mills G.B., Cho R.J., Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.
Modeling precision treatment of breast cancer.
Genome Biol. 14:R110.1-R110.14(2013)

PubMed=24279929; DOI=10.1186/2049-3002-1-20; PMCID=PMC4178206
Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R., Hirshfield K.M., Oltvai Z.N., Vazquez A.
The metabolic demands of cancer cells are coupled to their size and protein synthesis rates.
Cancer Metab. 1:20.1-20.13(2013)

PubMed=24389870; DOI=10.1038/srep03576; PMCID=PMC3880960
Strauch M., Ludke A., Munch D., Laudes T., Galizia C.G., Martinelli E., Lavra L., Paolesse R., Ulivieri A., Catini A., Capuano R., Di Natale C.
More than apples and oranges -- detecting cancer with a fruit fly's antenna.
Sci. Rep. 4:3576-3576(2014)

PubMed=24670534; DOI=10.1371/journal.pone.0092047; PMCID=PMC3966786
Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.
High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner.
PLoS ONE 9:E92047-E92047(2014)

PubMed=25960936; DOI=10.4161/21624011.2014.954893; PMCID=PMC4355981
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
OncoImmunology 3:e954893.1-e954893.12(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)

PubMed=25892236; DOI=10.1016/j.celrep.2015.03.050; PMCID=PMC4425736
Lawrence R.T., Perez E.M., Hernandez D., Miller C.P., Haas K.M., Irie H.Y., Lee S.-I., Blau C.A., Villen J.
The proteomic landscape of triple-negative breast cancer.
Cell Rep. 11:630-644(2015)

PubMed=26055192; DOI=10.1021/acs.jproteome.5b00375
Cifani P., Kirik U., Waldemarson S., James P.
Molecular portrait of breast-cancer-derived cell lines reveals poor similarity with tumors.
J. Proteome Res. 14:2819-2827(2015)

PubMed=26218769; DOI=10.1016/j.jchromb.2015.07.021
Willmann L., Schlimpert M., Halbach S., Erbes T., Stickeler E., Kammerer B.
Metabolic profiling of breast cancer: differences in central metabolism between subtypes of breast cancer cell lines.
J. Chromatogr. B 1000:95-104(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)

PubMed=26649326; DOI=10.1016/j.dib.2015.09.039; PMCID=PMC4644255
Cox T.R., Schoof E.M., Gartland A., Erler J.T., Linding R.
Dataset for the proteomic inventory and quantitative analysis of the breast cancer hypoxic secretome associated with osteotropism.
Data Brief 5:621-625(2015)

PubMed=27331101; DOI=10.1016/j.dib.2016.05.040; PMCID=PMC4905937
Aumsuwan P., Khan S.I., Khan I.A., Walker L.A., Dasmahapatra A.K.
Gene expression profiling and pathway analysis data in MCF-7 and MDA-MB-231 human breast cancer cell lines treated with dioscin.
Data Brief 8:272-279(2016)

PubMed=27377824; DOI=10.1038/sdata.2016.52; PMCID=PMC4932877
Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J., Vandesompele J.
Long non-coding RNA expression profiling in the NCI60 cancer cell line panel using high-throughput RT-qPCR.
Sci. Data 3:160052-160052(2016)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Miroo T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=27807467; DOI=10.1186/s13100-016-0078-4; PMCID=PMC5087121
Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J., Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.
A map of mobile DNA insertions in the NCI-60 human cancer cell panel.
Mob. DNA 7:20.1-20.11(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=28287265; DOI=10.1021/acs.jproteome.6b00470; PMCID=PMC5557415
Yen T.-Y., Bowen S., Yen R., Piryatinska A., Macher B.A., Timpe L.C.
Glycoproteins in claudin-low breast cancer cell lines have a unique expression profile.
J. Proteome Res. 16:1391-1400(2017)

PubMed=28889351; DOI=10.1007/s10549-017-4496-x
Saunus J.M., Smart C.E., Kutasovic J.R., Johnston R.L., Kalita-de Croft P., Miranda M., Rozali E.N., Vargas A.C., Reid L.E., Lorsy E., Cocciardi S., Seidens T., McCart Reed A.E., Dalley A.J., Wockner L.F., Johnson J., Sarkar D., Askarian-Amiri M.E., Simpson P.T., Khanna K.K., Chenevix-Trench G., Al-Ejeh F., Lakhani S.R.
Multidimensional phenotyping of breast cancer cell lines to guide preclinical research.
Breast Cancer Res. Treat. 167:289-301(2018)

PubMed=29273624; DOI=10.1101/gr.226019.117; PMCID=PMC5793780
Franco H.L., Nagari A., Malladi V.S., Li W.-Q., Xi Y.-X., Richardson D., Allton K.L., Tanaka K., Li J., Murakami S., Keyomarsi K., Bedford M.T., Shi X.-B., Li W., Barton M.C., Dent S.Y.R., Kraus W.L.
Enhancer transcription reveals subtype-specific gene expression programs controlling breast cancer pathogenesis.
Genome Res. 28:159-170(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=30971826; DOI=10.1038/s41586-019-1103-9
Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M., Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R., Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P., van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L., Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Nature 568:511-516(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=31092827; DOI=10.1038/s41467-019-10148-6; PMCID=PMC6520398
Liu K., Newbury P.A., Glicksberg B.S., Zeng W.Z.-D., Paithankar S., Andrechek E.R., Chen B.
Evaluating cell lines as models for metastatic breast cancer through integrative analysis of genomic data.
Nat. Commun. 10:2138.1-2138.12(2019)

PubMed=31978347; DOI=10.1016/j.cell.2019.12.023; PMCID=PMC7339254
Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. 3rd, Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K., Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.
Quantitative proteomics of the Cancer Cell Line Encyclopedia.
Cell 180:387-402.e16(2020)

PubMed=32782317; DOI=10.1038/s41598-020-70393-4; PMCID=PMC7419295
Risha Y., Minic Z., Ghobadloo S.M., Berezovski M.V.
The proteomic analysis of breast cell line exosomes reveals disease patterns and potential biomarkers.
Sci. Rep. 10:13572-13572(2020)

PubMed=34238275; DOI=10.1186/s12885-021-08511-2; PMCID=PMC8268371
Samson J., Derlipanska M., Zaheed O., Dean K.
Molecular and cellular characterization of two patient-derived ductal carcinoma in situ (DCIS) cell lines, ETCC-006 and ETCC-010.
BMC Cancer 21:790.1-790.20(2021)"